|
ISPOR Seventh
Annual European Congress
24-26 October 2004, CCH Congress Centrum Hamburg, Hamburg, Germany
“Focusing on Health Care Costs and
Outcomes in Health Care Decision-Making”
|
|
PROGRAM - Monday, October 25, 2004 |
|
|
7.00 – 8.00 |
Central
And Eastern European Breakfast– by invitation only
|
|
8.00 – 9.00 |
Institutional Council Breakfast– by invitation only
|
|
8.00 – 9.00 |
Contributed Poster Presentations – Session I
Viewing
Quality of Life Special Interest Group Forum
INDUSTRY AND REGULATORY
PERSPECTIVES ON TRANSLATING PATIENT REPORTED OUTCOME
(PRO)
MEASURES
This session will: compare and
contrast different approaches to translation and cultural validation
of instruments prior to their use in clinical trials; discuss the
potential costs and benefits of these approaches, including their
implications for bias and precision of results; and provide
regulatory perspectives on issues such as the role of certification
and validation requirements for multinational trials.
Moderator: Joyce Cramer BS,
Associate Research Scientist,
Yale University, New
Haven, CT, USA
TRANSLATION AND
LINGUISTIC VALIDATION OF PRO MEASURES: THE CURRENT STATE OF PLAY
Speaker:
Diane Wild MSc.,
Director,
Oxford Outcomes Ltd, Cassington,
Oxford, UK
CONSIDERING THE VALUE
ADDED OF VALIDATION OF TRANSLATIONS
Speaker:
Richard J. Willke PhD, Senior Director/Group Leader,
Worldwide Outcomes Research, Pfizer Inc., Peapack, NJ, USA
REGULATORY PERSPECTIVES
ON TRANSLATING PRO MEASURES
Speaker:
Laurie B. Burke RPh, Director, Study Endpoints and
Label Division, US Food and Drug Administration, Rockville, MD, USA
|
|
9.00
–10.30 |
Second
Plenary Session |
|
|
“COSTS AND OUTCOMES FOR DECISION-MAKING – FOURTH HURDLE”
Moderator:
Arne Heissel PhD,
Associate Research Scientist,
Senior Reimbursement Manager, Spinal, ENT & SNT,
Medtronic Europe Sarl, Tolochenaz, Switzerland
|
|
10.30
–10.45 |
Break
|
Coffee
Sponsored by MAPI Values
|
 |
|
|
|
10.45
–11.45 |
Contributed Podium
Presentations - Session I (4 podium groups with
4 presentations per group)
|
Cardiovascular I
Moderator: Jennifer Ehreth PhD, Director,
Reimbursement for Europe, Middle East and Africa, Medtronic
Europe, Tolochenez, Switzerland
CV1
A HEALTH ECONOMIC
EVALUATION OF ASPIRIN IN THE PRIMARY PREVENTION OF
CARDIOVASCULAR DISEASE
Lamotte M1,
Annemans L1, Evers T2,
Kubin M3,1HEDM, Meise, Belgium;
2Bayer Vital GmbH, Leverkusen, Germany; 3Bayer
HealthCare, Wuppertal, Elberfeld, Germany
CV2
CHOLESTEROL ATTAINMENT IN DYSLIPIDAEMIC TREATED PATIENTS AND
INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
Van
Ganse E1,
Souchet T2, Laforest L1,
Moulin P3, Bertrand M4,
Le Jeunne P5, Chretin S1,
Yin D6, Alemao E6, De
Pouvourville G7, 1Pharmacoepidemiology,
CHU-Lyon, Lyon, France; 2Merck Sharp & Dohme -
Chibret, Paris, France; 3Hopital Louis Pradel, Lyon,
France; 4CHU - Lille, Lille, France; 5Thales,
Boulogne Billancourt, France; 6Merck & Co, Whitehouse
Station, NJ, USA; 7INSERM U 537, Le Kremlin-Bicêtre,
France
CV3
NURSING HOME RESIDENTS WITH STROKE: CHANGES IN MANAGEMENT LEVELS
AND COSTS OVER A SIX YEAR PERIOD
O'Brien JA,
Duran P, Caro JJ, Caro Research Institute,
Concord, MA, USA
CV4
EVALUATION OF SURVIVAL AND ISCHAEMIC AND THROMBOEMBOLIC EVENT
RATES IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN THE
GENERAL POPULATION WHEN TREATED AND UNTREATED WITH WARFARIN
Jones M1,
Currie CJ2, McEwan P1,
1Cardiff University, Cardiff, Wales, UK; 2Cardiff
Research Consortium, Cardiff, Wales, UK
Infection
Moderator: Raimund Sterz
MD, PhD, Head of Health Economics, Knoll AG, Ludwigshafen, Germany
IN1
IMPACT OF RECENT RITONOVIR RE-PRICING ON COST-EFFECTIVENESS
ANALYSIS
Becker RV,
Stegman J, Ovation Research Group, Highland Park, IL, USA
IN2
IS PROVISION OF ANTI-VIRAL INFLUENZA TREATMENT A SOUND
INVESTMENT FOR PRIVATE AND PUBLIC EMPLOYERS IN THE UK?
Gyldmark M1,
Sander B2, 1F. Hoffmann – La Roche
Ltd, Basel, Switzerland; 2University Health Network,
Toronto, ON, Canada
IN3
ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED
SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN GREECE
Moeremans K1,
Annemans L1, Vandoros C2,
Liaropoulos L3, 1Health Economics and
Disease Management (HEDM), Brussel, Belgium; 2Janssen
Cilag Pharmaceutical, Pefki, Athens, Greece; 3University
of Athens, Athens, Greece
IN4
POPULATION-BASED EVALUATION OF FUTURE BURDEN OF DISEASE AND
COSTS RELATED TO CHRONIC HEPATITIS C AND ANTIVIRAL TREATMENT
STRATEGIES
Siebert U1,
Sroczynski G1, Aidelsburger P2,
Conrads-Frank A1, Esteban E3,
Wasem J2, Rossol S4,
Ravens-Sieberer U5, Wong JB6,
1Harvard Medical School, Boston, MA, USA; 2University
of Duisburg-Essen, Duisburg-Essen, Germany; 3Institute
for Medical Informatics, Biostatistics, and Epidemiology,
University of Munich, Munich, Germany; 4University of
Mainz, Ruesselsheim, Germany; 5Robert Koch-Institute,
Berlin, Germany; 6Tufts University School of
Medicine, Boston, MA, USA
Methods & Concepts I
Moderator:
Maria Kubin MD, Director/Head, Global Health Economics
and Outcomes Research, Bayer HealthCare, Wuppertal, Germany
MC1
COMPLIANCE, ADHERENCE, AND PERSISTENCE: A COMPARISON OF THREE
METHODOLOGIES FOR EVALUATING PATIENT COMPLIANCE USING
PRESCRIPTION CLAIMS DATA
LaFleur J,
Thompson C, Biskupiak J, Stockdale W,
Oderda GM, Brixner D, University of Utah, Salt Lake
City, UT, USA
MC2
CORRECTING FOR COMPENSATING MECHANISMS RELATED TO PRODUCTIVITY
COSTS IN ECONOMIC EVALUATIONS OF HEALTH CARE PROGRAMS
Severens JL1,
Koopmanschap MA2, Meerding W2,
1Maastricht University, Maastricht, The Netherlands;
2Erasmus Medical Centre, Rotterdam, The Netherlands
MC3
QALYS LACK QUALITY IN PAEDIATRIC CARE: A CRITICAL REVIEW OF
PUBLISHED COST-UTILITY STUDIES IN CHILD HEALTH
Griebsch I,
Brown J, University of Bristol, Bristol, UK
MC4
FLEXIBILITY AND TRANSPARENCY OF BAYESIAN NETWORKS: MODELING THE
ECONOMIC IMPACT OF DRUG-ELUTING CORONARY STENTS
Marchetti M,
Barosi G, IRCCS Policlinico San Matteo, Pavia, Italy
Quality of Life I
Moderator:
Jan van
Busschbach PhD, Institute for Medical Psychology and
Psychotherapy, Erasmus University, Rotterdam, The Netherlands
QL1
AGREEMENT BETWEEN PATIENTS’ AND CLINICIANS’-REPORTED OUTCOMES IN
LIPODYSTROPHY (HIV/AIDS)
Duracinsky M1,
Acquadro C2, Wu A3,
Chassany O4, 1Hopital de Bicetre, Le
Kremlin-Bicetre, France; 2MAPI Research Institute,
Lyon, France; 3Johns Hopkins University, Baltimore,
MD, USA; 4Assistance Publique - Hopitaux de Paris,
Paris, France
QL2
THE HEALTH RELATED QUALITY OF LIFE IN PARKINSON’S DISEASE IN
GERMANY
Spottke EA1,
Peter H2, Reuther M1,
Campenhausen S1, Berger K3,
Machat O4, Koehne-Volland R4,
Oertel WH2, Dodel R1, 1Friedrich-Wilhelms-University,
Bonn, Germany; 2Philipps University, Marburg,
Germany; 3MERG Medical Economics Research Group,
München, Germany; 4Metronomia, Munich, Germany
QL3
QUALITY OF LIFE OF GASTROESOPHAGEL REFLUX DISEASE PATIENTS
Di
Stasi F,
Mantovani LG, University of Milan, Milan, Italy
QL4
PATIENT-RATED UTILITIES IN POSTMENOPAUSAL EARLY BREAST CANCER (EBC):
A CROSS-COUNTRY COMPARISON
Sorensen SV1,
Brown R2, Benedict A2,
Flood E1, Revicki D1,
1MEDTAP International Inc, Bethesda, MD, USA; 2MEDTAP
International Inc, London, UK
|
|
|
11.45
–13.15 |
|
Lunch
Sponsored by Caro
Research |
 |
Exhibits & Contributed Poster Presentations–Session I
(see poster
presentations at:
http://www.ispor.org/congresses/germany1004/index.asp) |
|
13.15
–14.15 |
Contributed
Podium Presentations – Session II (4 podium groups with
4 presentations per group) |
| |
|
Cardiovascular II
Moderator:
Florian Mitscherlich, Managing Partner, Amiet Mitserlich
+ Partner GmbH, Solothurn, Switzerland
CV5
THE COSTS AND EFFECTS OF CLOPIDOGREL IN COMPARISON TO ASA OR
PLACEBO FOR SEVERAL PATIENT POPULATIONS IN DENMARK
Heeg
B1,
Serup-Hansen N2, Buskens E3,
Ruppert A4, Boström P5,
Hout van BA3, 1PharMerit, Capelle a/d
IJssel, Zuid Holland, The Netherlands; 2Sanofi-Synthelabo,
Brøndby, Denmark; 3PharMerit, Capelle a/d IJssel,
The Netherlands; 4Bristol-Myers Squibb, Bromma, Sweden;
5Sanofi-Synthelabo, Bromma, Sweden
CV6
WHAT IS THE ADDED VALUE OF HEALTH RELATED QUALITY OF LIFE (HRQL)
DATA? AN EXAMPLE FROM THE INTERNATIONAL SUBARACHNOID ANEURYSM
TRIAL (ISAT)
Lloyd A1,
Scott R2, Carpenter K2,
1MEDTAP International, London, UK; 2Oxford
University, Oxford, UK
CV7
MODELLING SURVIVAL AND COSTS IN SWITZERLAND OF NESIRITIDE VERSUS
INOTROPIC THERAPY FOR ACUTE DECOMPENSATED HEART FAILURE
Slivinskas J1,
Levy AR1, Sendi P2,
Brunner-La Rocca HP2, Gagnon YM1,
Briggs A1, 1Occam Outcomes Ltd,
Vancouver, BC, Canada; 2University Hospital, Basel,
Switzerland
CV8
PHARMACOECONOMIC CONSEQUENCES OF PRIMARY AND SECONDARY
PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLIC
Praznovcova L1,
Strnad L2, 1Charles University,
Faculty of Pharmacy, Hradec Kralove, Czech Republic; 2University
of Management, Hradec Kralove, Czech Republic
Cancer
Moderator:
Diana
Brixner PhD, Associate Professor/Department Chair,
University of Utah, Salt Lake City, UT, USA
CN1
TRENDS IN OUTCOMES AND COSTS FOR U.S. PATIENTS WITH ADVANCED
NON-SMALL LUNG CANCER 1994-2001
Ramsey SD,
Howlader N, Fred Hutchinson Cancer Research Center,
Seattle, WA, USA
CN2
COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB + CHOP VERSUS CHOP IN
PATIENTS WITH AGGRESSIVE NON-HODGKIN LYMPHOMA
Berto P1,
Morsanutto A2, Lopatriello S1,
1PBE Consulting, Verona, VR, Italy; 2Università
di Milano, Milano, Italy
CN3
COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-α) PLUS
LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE
CHRONIC MYELOID LEUKEMIA (CML) IN THE NETHERLANDS
Groot MT1,
Anstrom KD2, Reed SD3,
Uyl-de Groot CA1, 1ErasmusMC
University Medical Center, Rotterdam, The Netherlands; 2Duke
Clinical Research Institute, Durham, NC, USA; 3Duke
Clinical Research Institute, Durham, NC, USA
CN4
COST-EFFECTIVENESS OF SAMARIUM-153-EDTMP COMPARED TO
CONVENTIONAL PAIN THERAPY IN GERMANY
Fricke FU1,
Müller UJ2, Pinkert J3,
Rudolph I4, Fischer M5, 1Fricke
& Pirk GmbH, Nuremberg, Bavaria, Germany; 2Schering
AG, Germany; 3Schering Deutschland GmbH, Germany;
4Jenapharm GmbH, Germany; 5Klinikum Kassel,
Germany
Methods & Concepts II
Moderator:
Farzana Malik PhD, Sr. Reimbursement, Medtronic Europe Sarl,
Tolochenez, Switzerland
MC5
VISUAL ANALOGUE SCALES: ARE THE ELICITED PREFERENCES ANALOGUE?
Akunne AF,
Bridges J, Sauerborn R
University of Heidelberg, Heidelberg, Baden-Wuerrtembe, Germany
MC6
PRODISQ A MODULAR QUESTIONNAIRE ON PRODUCTIVITY AND DISEASE FOR
ECONOMIC EVALUATION STUDIES IN PATIENT SETTINGS AND
ORGANISATIONAL SETTINGS
Koopmanschap MA1,
Meerding W1, Evers S2,
Severens JL2, Burdorf A1,
Brouwer WB1, 1Erasmus Medical Centre,
Rotterdam, The Netherlands; 2Maastricht University,
Maastricht, The Netherlands
MC7
USING STATED RISK-BENEFIT TRADEOFF PREFERENCES TO IDENTIFY
POTENTIAL THERAPEUTIC RISK-MANAGEMENT PROBLEMS
Johnson FR,
Andrews EB
1Research Triangle Institute, Research Triangle Park,
NC, USA
MC8
COMPARING THE INTERVAL PROPERTIES OF HEALTH-STATE VALUATIONS
MEASURED USING THE VISUAL ANALOGUE SCALE AND RANK-BASED SCALING
Krabbe PFM1,
Salomon JA2, Murray CJL2,
1University Medical Centre Nijmegen, Nijmegen,
Netherlands; 2Harvard University, Boston, MA, USA
Quality of Life II
Moderator:
Thomas
Mittendorf MSc, Research Fellow, Centre for Health Economics
and Health System Research, University of Hannover, Hannover,
Germany
QL5
VALIDATION OF THE GERMAN PROSTATE SPECIFIC MODULE (PSM)
Bestmann B1,
Rohde V2, Weidner W2,
Kuechler T1, 1Reference Center Quality
of Life in Oncology, Kiel, Schleswig-Holste, Germany; 2University
of Giessen, Giessen, Hessen, Germany
QL6
THE BARTHEL PREFERENCE INDEX (BPI): A NEW CONDITION-SPECIFIC
PREFERENCE INDEX (COPI) FOR USE IN STROKE
Banks JL1,
Netten A2, Ryan M3,
Watson V3, Salas M4, 1Health
Outcomes Strategy Group, Boston, MA, USA; 2University
of Kent at Canterbury, Canterbury, Kent, UK; 3University
of Aberdeen Medical School, Aberdeen, UK; 4Erasmus
University Medical School, Rotterdam, The Netherlands
QL7
VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE
THE SEVERITY OF LOWER URINARY TRACT SYMPTOMS IN UNCOMPLICATED
URINARY TRACT INFECTION: THE UTI SYMPTOM ASSESSMENT (USA)
QUESTIONNAIRE
Clayson DJ1,
Wild DJ1, Keating K2,
Gondek K2, 1Oxford Outcomes Ltd,
Oxford, Oxon, UK; 2Bayer HealthCare Pharmaceuticals,
West Haven, CT, USA
QL8
DEVELOPMENT AND VALIDATION OF THE DIAPASON: A TREATMENT
SATISFACTION QUESTIONNAIRE FOR INDIVIDUALS WITH TYPE-2 DIABETES
Trudeau E1,
Seignobos E1, Varroud-Vial M2,
Comte S3, 1Mapi values, Lyon,
France; 2Réseau REVEDIAB; 3Merck Santé,
Paris, France |
|
|
14.15
–14.30 |
|
Break
- Coffee
Sponsored by MAPI Values
|
|
|
|
|
14.30
–15.30 |
Contributed
Podium Presentations – Session III (4 podium groups with
4 presentations per group) |
| |
|
Mental Health
Moderator: Rosanna
Tarricone PhD, Economic Appraisals, CERGAS, Milan, Italy
MH1
INCREMENTAL COST-EFFECTIVENESS OF THREE CLASSES OF
ANTI-DEPRESSANTS: RESULTS FROM A UK RANDOMISED TRIAL
Longworth L1,
Buxton MJ2, Kendrick AR3,
Chatwin J3, Peveler RC3, 1National
Institute for Clinical Excellence, London, UK; 2Brunel
University,Uxbridge, Middlesex, UK; 3University of
Southampton, Southampton, UK
MH2
MODELING ANTIPSYCHOTICS MARKET SHARE EVOLUTION TREATMENT
Riou-França L1,
Westerloppe J2, Launois R1,
1REES France, PARIS, France; 2Bristol-Myers
Squibb, Rueil-Malmaison, Paris, France
MH3
SCHIZOPHRENIA AND QUALITY OF LIFE ASSESSMENTS
Adams J1,
LeReun C1, Crowley S2,
Nand V2, Eggleston A2,
1M-TAG Australia Pty Ltd, Chatswood, NSW, Australia;
2Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia
MH4
ADHD-RELATED PATIENT AND FAMILY BURDEN: BASELINE RESULTS FROM
THE OBSERVATIONAL STUDY ADORE IN GERMANY
Döpfner M1,
Rothenberger A2, Finnern H3,
Lorenzo M4, Ralston S4,
Dittmann R3, 1University of Cologne,
Cologne, Germany; 2Georg-August-University Göttingen,
Göttingen, Germany; 3Lilly Deutschland GmbH, Bad
Homburg, Germany; 4Eli Lilly and Company Ltd,
Windlesham, UK
Diabetes
Moderator: Mark Nuijten MBA, MD, PhD, Director of
European Business Development, MEDTAP Intrenational, Jisp, The
Netherlands
DB1
ASSOCIATION BETWEEN ANTIPSYCHOTIC DRUGS AND DIABETES MELLITUS: A
PHARMO STUDY
Erkens JA1,
Pugner K2, Lapuerta P3,
Herings RMC1, 1PHARMO Institute,
Utrecht, Netherlands; 2Bristol-Myers Squibb
International Corporation, Waterloo, Belgium; 3Bristol-Myers
Squibb Company, Princeton, NJ, USA
DB2
LABOR MARKET EFFECTS OF INSULIN DEPENDENT AND NON-INSULIN
DEPENDENT DIABETES AMONG CANADIAN LABOR FORCE
Farahati F,
McMaster University, Hamilton, Ontario, Canada
DB3
DECREASED RATES OF MAJOR HYPOGLYCAEMIC EVENTS LEAD TO IMPROVED
LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70
VERSUS BIPHASIC HUMAN INSULIN 30 IN TYPE 2 DIABETIC SUBJECTS IN
DANISH, FINNISH, GERMAN, NORWEGIAN, SPANISH, SWEDISH, AND UK
SETTINGS
Lammert M1,
Palmer AJ2, Roze S2,
Minshall ME3, Valentine WJ2,
1Novo Nordisk A/S, Bagsvaerd, Denmark; 2CORE
Center for Outcomes Research, Binningen/Basel, Switzerland;
3CORE-USA, Fishers, IN, USA
DB4
PROOF OF CONCEPT OF A WIRELESS APPROACH FOR ENABLING
COMMUNICATIONS BETWEEN GERMAN PHYSICIANS AND THEIR PATIENTS WITH
TYPE 2 DIABETES TREATED WITH NATEGLINIDE
Netherton DR1,
LeVine P2, 1InfoMedics, Inc,
Woburn, MA, USA; 2InfoMedics, Inc, Philadelphia, PA,
USA
Utilities & Costs
Moderator: Paul Krabbe
PhD, Senior Researcher, Medical Technology Assessment,
University Medical Center
Nijmegen, The Netherlands
UC1
HEALTH ECONOMIC COMPARISON OF CONTINUOUS SUBCUTANEOUS INSULIN
INFUSION WITH MULTIPLE DAILY INJECTION FOR THE TREATMENT OF TYPE
1 DIABETES IN THE UK
Zakrzewska K1,
Roze S2, Valentine WJ2,
Palmer AJ2, 1Medtronic AG, Tolochenaz,
Switzerland; 2CORE Center for Outcomes Research,
Binningen/Basel, Switzerland
UC2
PATIENTS' PREFERENCES FOR INGUINAL HERNIA REPAIR
Fargher EA1,
Deans GT2, Cook GA2,
Davies LM1
1University of Manchester, Manchester, UK; 2Stepping
Hill Hospital, Stockport, UK
UC3 A
FIVE-LEVEL VERSION OF EQ-5D
Kind
P1,
Macran S2, 1Outcomes Research
Group, York, UK; 2University of York, York, UK
UC4
VARIATION IN ADL FUNCTIONING WITHIN BARTHEL INDEX
SCORES:IMPLICATIONS FOR STROKE CLINICAL TRIALS AND PRACTICE
Banks JL1,
Netten A2, Pollok J3, Van
de Peer L3, Salas M4, 1Health
Outcomes Strategy Group, Boston, MA, USA; 2University
of Kent at Canterbury, Canterbury, UK; 3Kent and
Canterbury Hospital, Canterbury, UK; 4Erasmus
University Medical School, Rotterdam, The Netherlands
Health Policy I
Moderator: Jens Grueger PhD, Head of Pricing
and Health Economics Department, Novartis Pharmaceuticals AG,
Basel, Switzerland
HP1
THE RELATIONSHIP BETWEEN HEALTH INSURANCE TYPE AND COSTS OF
PRESCRIBED DRUGS
Ngorsuraches S,
Ungsupanit J, Faculty of Pharmaceutical Sciences, Prince
of Songkla University, Hatyai, Songkla, Thailand
HP2
EVALUATION OF CONDITIONAL REIMBURSEMENT AS A POLICY-INSTRUMENT
Niezen-Van der Zwet MGH1,
Stolk EA1, Eyck A2,
Niessen L1, Stoevelaar HJ1,
1Erasmus Medical Center, Rotterdam, The Netherlands;
2ETC Crystal, Leusden, The Netherlands
HP3
PHARMACOECONOMIC EDUCATION AT NON-US COLLEGES OF PHARMACY
Nwokeji ED,
Rascati K, The University of Texas at Austin, Austin, TX,
USA
HP4
DRUG COSTS DEVELOPMENT AFTER PATENT EXPIRY IN THE NETHERLANDS
Boersma C,
Bos JM, Klok RM, Postma MJ, Groningen
University Institute for Drug Exploration / University of
Groningen Research Institute of Pharmacy (GUIDE/GRIP),
Groningen, Groningen, The Netherlands
|
|
|
15.30
–15.45 |
|
Break
- Coffee
Sponsored by MAPI Values
|
|
|
|
|
15.45
–16.45 |
Issues Panels
– Session I
(4 panels)
FDA DRAFT GUIDANCE FOR
THE INDUSTRY ON THE ASSESSMENT OF PATIENT REPORTED OUTCOMES – WHAT ARE
THE IMPLICATIONS FOR GLOBAL CLINICAL RESEARCH?
Moderator: Patrick Marquis MBA, MD,
Managing
Director, Mapi Values, Boston, MA, USA
Panelists:
David W. Miller PhD, Vice
President, Global Health Outcomes, GlaxoSmithKline, Research Triangle
Park, NC, USA; Ingela Wiklund PhD, Professor, Senior Principal
Scientist, Global Director Outcomes Research, Astra Zeneca, Molndal,
Sweden
PHARMACOECONOMIC STUDIES
POST-LAUNCH: WHO NEEDS THEM?
Moderator: Adrian Towse MA,
Director,
Office of
Health Economics, London, UK
Panelists:
Martin Buxton BA Soc Sci, Professor, Brunel
University, Uxbridge, Middlesex, UK; Rosario Trindade,
Infarmed, Lisbon, Portugal; Claude Le Pen PhD, Aremis Consultants
and Paris Dauphine University, Paris, France; Michael Drummond
PhD, Director, University of York, York, UK
WHAT IS GOING ON IN
GERMANY?
Moderators:
Marianne Van Genugten,
Project Director, MAPI Values, Houten, The Netherlands;
Jeanni Van Loon MSc,
Development Director Europe, Mapi
Values, Houten, The Netherlands
Panelists:
York Zoellner MS, PharmD, Health Economics Manager , Solvay,
Hannover, Germany; Reiner Leidl PhD, Department of Health
Economics, Ludwig-Maximilians-University, Munich, Germany
INDUSTRY’S VS. STATUTORY
HEALTH INSURANCE’S VS. UNIVERSITY’S RESEARCH INTERESTS – IS THERE MUTUAL
BENEFIT IN EPIDEMIOLOGICAL AND OUTCOMES RESEARCH?
Moderator: Bernd Brüggenjürgen
MD, MPH,
Coordinator, Health
Economics, Berlin, Germany
Panelists: Wolfgang Meyer-Sabellek Prof, PhD,
Professor, AstraZeneca, Wedel, Germany;
Christoph
Straub, Techniker
Krankenkasse, Hamburg, Germany; Stefan N. Willich Prof, PhD,
Professor,
University Medicine Berlin, Charité, Berlin, Germany |
|
16.45
–17.00 |
|
Break
- Coffee
Sponsored by MAPI Values
|
|
|
|
|
17.00
–18.00 |
Issues Panels
– Session II
(4 panels)
ECONOMIC ISSUES IN RISK
MANAGEMENT
Moderator:
Adrian Towse
MA,
Director, Office of Health Economics, London, UK
Panelists: Lou Garrison PhD,
Professor, University of Washington, Seattle, WA, USA;
Adrian Towse MA,
Director, Office of Health Economics, London, UK;
Thomas Lonngren, Director, European Medicines Agency, EMEA, Canary
Wharf, London, UK
CHALLENGES TO ATTAIN THE
TARGETED PRICE AND MAXIMUM REIMBURSEMENT IN ALL EUROPEAN COUNTRIES
Moderator:
Jeanni Van
Loon MSc,
Development Director Europe, Mapi Values, Houten, The Netherlands
Panelists:
Guido Van den Boom PhD, Health Outcomes Manager, Novartis Pharma
BV, Arnhem, The Netherlands; Jens Grueger PhD, Head of Pricing
and Health Economics Department, Novartis Pharma AG, Basel, Switzerland;
H. Van Dieten MSc, Policy Advisor Pharmacoeconomics,
Health Care Insurance Board (CVZ), Diemen, The Netherlands
SCIENCE OR ADVERTISING:
HOW EDITORS DRAW THE LINE
Moderator:
C. Daniel Mullins PhD,
Professor and Chair of Pharmaceutical Health Services Research,
University of Maryland, Baltimore, MD, USA
Panelists:
Christopher Carswell,
Editor,
Pharmacoeconomics, Adis International, Auckland, New Zealand; Alan
Lyles MPH, RPh, Professor, University of
Baltimore, Baltimore,
MD, USA; Josephine Mauskopf PhD, Division Director, Global Health
Economics, RTI Health Solutions, RTI International, Research Triangle
Park, NC, USA
DO DECISION-MAKERS HAVE
LESS CREDIBILITY WITH MODELING RESULTS?
Moderator:
Uwe Siebert MD, MPH, MSc,
Decision Scientist, Director of the Cardiovascular Research Program,
Institute for Technology Assessment, Massachusetts General Hospital,
Harvard Medical School, Boston, MA, USA and Director of the Program on
Health Technology Assessment and Decision Sciences (HTA&DS), Institute
for Medical Informatics, Biostatistics, and Epidemiology, University of
Munich, Munich, Germany.
Panelists:
Bernhard Gibis MD, MPH, Head
of Department of Quality Assurance, National Association of Statutory
Health Insurance Physicians (NASHIP), Berlin, Germany; Michael
Drummond PhD, Director, Centre for Health Economics, University of
York, York, UK.
|
|
18.00
–18.10 |
Overview of the Medication Compliance Special Interest Group
Moderator: Joyce A. Cramer BS,
Associate Research Scientist, Department of Psychiatry, Yale University
School of Medicine, New Haven, CT, USA and Chair, Medication Compliance
SIG |
|
18.10
–18.20 |
Definitions of Compliance/Adherence, Persistence
Speaker: Anita Burrell MS,
Global Health Outcomes, Aventis Pharmaceuticals, Bridgewater, NJ, USA
|
|
18.20
–18.30 |
Approaches to Methods of Analysis
Speaker: Femida Gwadry-Sridhar PhD,
University of Western Ontario, London, ON, Canada and
Michael Nichols PhD,
Associate Professor, School of Pharmacy, University of Southern
California, Los Angeles, CA, USA
|
|
18.30
–18.40 |
Approaches to Economic Analysis
Speaker: Dyfrig Hughes PhD MRPharmS,
Senior Research Fellow, University of Wales, Bangor, N. Wales
|
|
18.40
–18.45 |
Approaches to Dissemination of Information (Education) and Updating the
Web-based Bibliography
Speaker: Joyce A. Cramer BS,
Associate Research Scientist, Department of Psychiatry, Yale University
School of Medicine, New Haven, CT, USA and Chair, Medication Compliance
SIG
|
|
18.45
–19.00 |
Development of Guidelines on Compliance/Adherence, Persistence Analysis
Speaker: David Nau PhD,
Associate Professor, University of Michigan, Ann Arbor, MI, USA and
Andrew Peterson PhD, Assistant Professor, Universoty of the Sciences
in Philadelphia, Philadelphia, PA, USA
|
|
18.00
–19.00 |
ISPOR Medication Compliance Special
Interest Group Forum
Issues in Medication Compliance and
Persistence Research:
This
session will examine major applied research issues that are
important for the assessment of medication
compliance/adherence/persistence. The discussion will review the
definitions, methods of analyses, economic impact, and educational
components currently under development by the SIG. Panelists will
discuss the approaches with comments and suggestions to help move
ISPOR into the forefront of medication analyses and enhancements.
Chair:
Joyce A. Cramer,
Associate Research Scientist, Department of Psychiatry, Yale
University School of Medicine, New Haven, CT, USA
Chair, Medication Compliance SIG
Panelists:
Anita
Burrell MS, Global
Health Outcomes, Aventis Pharmaceuticals, Bridgewater, NJ, USA
Dyfrig Hughes PhD MRPharmS,
Senior Research Fellow, University
of Wales, Bangor, N. Wales
Femida
Gwadry-Sridhar PhD,
University of Western Ontario, London, ON, Canada
Michael
Nichols PhD, Associate
Professor, School of Pharmacy, University of Southern California,
Los Angeles, CA, USA
David Nau
PhD, Associate
Professor, University of Michigan, Ann Arbor, MI, USA
Andrew
Peterson PhD, Assistant
Professor, University of the Sciences in Philadelphia, Philadelphia,
PA, USA
PROGRAM
|
18:00 |
Overview of the Medication Compliance Special Interest Group
(Joyce Cramer) |
|
18:10 |
Definitions of Compliance/Adherence, Persistence
(Anita Burrell) |
|
18:20 |
Approaches to methods of analysis (Michael Nichols, Femida Gwadry-Sridhar) |
|
18:30 |
Approaches to economic analysis (Dyfrig Hughes) |
|
18:40 |
Approaches to dissemination of information
(education) and updating the web-based bibliography (Joyce
Cramer) |
|
18:45 |
Development of Guidelines on Compliance/Adherence,
Persistence analyses (David Nau, Andrew Peterson) |
|
19:00 |
To the poster reception |
|
|
|
|
|
18.00
–20.00 |
Exhibitors’ Wine &
Cheese Reception, Poster Presentations – Session II
See Poster Presentations –
Session II
|
Reception sponsored by HealthCore, Inc. |
 |
|
|
20:00-21:00
|
ISPOR Student Forum & Student Icebreaker
|
|
|
ISPOR Thanks Hoffman-La Roche and HealthCore for the ISPOR Student
Travel Grants
Launch of the
European Student Chapter
The ISPOR European
Student Chapter, a student led group studying in the field of health
economics, outcomes research and pharmacoeconomics within academic
institutions anywhere in Europe. Students interact via the ISPOR
website, the ISPOR European Student Chapter website, and more. Join us
to learn how to get involved! Links to useful resources will also be
discussed. The student icebreaker will follow.
Speakers:
Larry Humble, 2004-05 ISPOR Student Network Chair & Doctoral
Student, University of Louisiana at Monroe, Monroe, LA, USA and Zeba
Khan PhD, Head Health Economics & Pricing, Cardiovascular and
Metabolism Business Franchise, Novartis Pharma AG |
|
7th Annual European Congress Main Pagee
|
|
